FDAnews
www.fdanews.com/articles/85891-reata-to-begin-testing-rta-402

REATA TO BEGIN TESTING RTA 402

April 7, 2006

Reata Pharmaceuticals has reported that its third development candidate, RTA 402, has received FDA clearance to begin clinical testing in patients with solid tumors, lymphoma, and myeloma. A clinical trial has been initiated with this agent at the M. D. Anderson Cancer Center in Houston, Texas.

RTA 402 is a novel targeted cancer therapy with a unique mechanism of action. It exploits fundamental physiological differences between cancerous and noncancerous cells by modulating oxidative stress response pathways. As a result, the drug is toxic to cancer cells but induces protective antioxidant and anti-inflammatory responses in normal cells.